

Canine CCN3 / NOV Protein (His Tag)

Catalog Number: 70043-D08H



Sino Biological Inc.

Biological Solution Specialist

General Information

Gene Name Synonym:

NOV

Protein Construction:

A DNA sequence encoding the canine NOV(XP_532317.3) (Met1-Met353) was expressed with a C-terminal polyhistidine tag.

Source: Canine

Expression Host: Human Cells

QC Testing

Purity: > 85 % as determined by SDS-PAGE

Endotoxin:

< 1.0 EU per µg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Gln 29

Molecular Mass:

The recombinant canine NOV comprises 336 amino acids and has a predicted molecular mass of 36.9 kDa. The apparent molecular mass of the protein is approximately 40-47 kDa in SDS-PAGE under reducing conditions due to glycosylation.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.


Usage Guide

Storage:

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

SDS-PAGE:



Reconstitution:

Detailed reconstitution instructions are sent along with the products.

Protein Description

Protein NOV homolog, also known as Nephroblastoma-overexpressed gene protein homolog, NOV, and CCN3, is secreted protein which belongs to the CCN family. CCN3 expression was observed in a broad variety of tissues from the early stage of development. It contains one CTCK (C-terminal cystine knot-like) domain, one IGFBP N-terminal domain, one TSP type-1 domain, and one VWFC domain. CCN3, a founding member of the CCN family of growth regulators, was linked with hematology in 2003 when it was detected in human serum. CCN3 acts through the core stem cell signalling pathways including Notch and Bone Morphogenic Protein, connecting CCN3 with the modulation of self-renewal and maturation of a number of cell lineages including hematopoietic, osteogenic and chondrogenic. Altered CCN3 expression is associated with numerous solid tumors including glioblastoma, melanoma, adrenocortical tumours, prostate cancer and bone malignancies including osteosarcoma. CCN3 may affect the extracellular environment of the niche for hematopoietic stem cells. CCN3 has emerged as a key player in stem cell regulation, hematopoiesis and a crucial component within the bone marrow microenvironment.

References

1. Lombet A. et al., 2003, Cell Commun Signal. 1?(1): 1.
2. Katsube K. et al., 2009, J Cell Commun Signal. 3?(2): 135-45.
3. McCallum L. et al., 2009, Blood Rev. 23?(2): 79-85.
4. McCallum L.J. et al., 2009, Cell Commun Signal. 3?(2):115-24.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Fax :+86-10-51029969 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>